| Recurrence rates in patients with cervical cancer treated with abdominal versus minimally invasive radical hysterectomy: a multi-institutional retrospective review study S Uppal, PA Gehrig, K Peng, KL Bixel, K Matsuo, MH Vetter, BA Davidson, ... Journal of Clinical Oncology 38 (10), 1030-1040, 2020 | 153 | 2020 |
| Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer LA Meyer, AM Cronin, CC Sun, K Bixel, MA Bookman, MC Cristea, ... Journal of Clinical Oncology 34 (32), 3854, 2016 | 150 | 2016 |
| Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target U Saini, S Naidu, AC ElNaggar, HK Bid, JJ Wallbillich, K Bixel, C Bolyard, ... Oncogene 36 (2), 168-181, 2017 | 116 | 2017 |
| Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia MH Vetter, B Smith, J Benedict, EM Hade, K Bixel, LJ Copeland, DE Cohn, ... American journal of obstetrics and gynecology 222 (1), 60. e1-60. e7, 2020 | 89 | 2020 |
| Olaparib in the management of ovarian cancer K Bixel, JL Hays Pharmacogenomics and personalized medicine, 127-135, 2015 | 70 | 2015 |
| Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer KM Esselen, AM Cronin, K Bixel, MA Bookman, RA Burger, DE Cohn, ... JAMA oncology 2 (11), 1427-1433, 2016 | 56 | 2016 |
| Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions MH Vetter, A Khan, FJ Backes, K Bixel, DE Cohn, LJ Copeland, JM Fowler, ... Gynecologic Oncology 152 (2), 316-321, 2019 | 35 | 2019 |
| Role of olaparib as maintenance treatment for ovarian cancer: the evidence to date L Montemorano, MDS Lightfoot, K Bixel OncoTargets and therapy, 11497-11506, 2019 | 32 | 2019 |
| Placental origins of angiogenic dysfunction in mirror syndrome K Bixel, M Silasi, CM Zelop, KH Lim, Z Zsengeller, IE Stillman, S Rana Hypertension in pregnancy 31 (2), 211-217, 2012 | 32 | 2012 |
| A rare case of NUT midline carcinoma A Ball, A Bromley, S Glaze, CA French, P Ghatage, M Köbel Gynecologic oncology case reports 3, 1-3, 2013 | 29 | 2013 |
| Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma K Bixel, U Saini, H Kumar Bid, J Fowler, M Riley, R Wanner, ... International journal of cancer 141 (9), 1856-1866, 2017 | 28 | 2017 |
| PARP inhibition and gynecologic malignancies: a review of current literature and on-going trials SM Crafton, K Bixel, JL Hays Gynecologic oncology 142 (3), 588-596, 2016 | 25 | 2016 |
| Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases. S Uppal, P Gehrig, MH Vetter, BA Davidson, BF Lees, LL Brunette, ... Journal of Clinical Oncology 37 (15_suppl), 5504-5504, 2019 | 24 | 2019 |
| PARP inhibitors in gynecologic cancers: what is the next big development? M Lightfoot, L Montemorano, K Bixel Current oncology reports 22 (3), 29, 2020 | 20 | 2020 |
| STAT3/PIAS3 levels serve as “early signature” genes in the development of high-grade serous carcinoma from the fallopian tube U Saini, AA Suarez, S Naidu, JJ Wallbillich, K Bixel, RA Wanner, J Bice, ... Cancer research 78 (7), 1739-1750, 2018 | 20 | 2018 |
| Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy BA Davidson, G Broadwater, A Crim, R Boccacio, K Bixel, F Backes, ... Gynecologic Oncology 152 (3), 554-559, 2019 | 19 | 2019 |
| Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis DA Barrington, PJ Haight, C Calhoun, C Tubbs, DE Cohn, KL Bixel Gynecologic Oncology 162 (3), 626-630, 2021 | 14 | 2021 |
| ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer. KL Bixel, MM Leitao, DM Chase, A Quick, PC Lim, RN Eskander, ... Journal of Clinical Oncology 40 (16_suppl), TPS5605-TPS5605, 2022 | 13 | 2022 |
| Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and … CA Thomson, TE Crane, A Miller, MA Gold, M Powell, K Bixel, L Van Le, ... Gynecologic oncology 170, 11-18, 2023 | 10 | 2023 |
| Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer FJ Backes, L Wei, M Chen, K Hill, K Dzwigalski, M Poi, M Phelps, R Salani, ... Gynecologic Oncology 162 (3), 619-625, 2021 | 9 | 2021 |
